Copper tetramibi tetrafluoroborate 1mg kit for radiopharmaceutical preparation
Requires a prescription from a doctor or prescriber
Shortage warning
Current supply issues
High shortage warning
Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-medi…
Affected areas: UK
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
MHRA licensed products
View all licensed products for Copper tetramibi tetrafluoroborate on the MHRA register
Cardiovis 1mg kit for radiopharmaceutical preparation
Stamicis 1mg kit for radiopharmaceutical preparation
Technescan MIBI 1mg kit for radiopharmaceutical preparation
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
1974–2026
Showing the 50 most relevant studies, sorted by most relevant.
H. Karimi-Maleh, O. Arotiba
Journal of colloid and interface science, 2020
Po-Yu Chen, I-Wen Sun
Electrochimica Acta, 1999
José Barluenga, Henar Vázquez-Villa, Alfredo Ballesteros, et al.
Organic Letters, 2002
Hongli Liu, Bin Sun, Zaiqi Li, et al.
Angewandte Chemie, 2024
Mustafa K. A. Mohammed, Raed Alazzawi, Hadi Hassan Jasim, et al.
Optical Materials, 2022
Sanjeev K. Garg, Raj Kumar, Asit K. Chakraborti
Tetrahedron Letters, 2005
Changyuan Yan, Zixuan Chen, Hao Huang, et al.
Angewandte Chemie, 2023
Hongzhuo Song, Xuemei Zhang, Gang Chen, et al.
Organic letters, 2023
Hongyuan Zhang, Qian Zhang, Xiaona Ji, et al.
Molecules, 2025
Copper ions (Cu2+), indispensable in physiological processes yet toxic at elevated concentrations, require sensitive on-site monitoring. Here, a portable fluorescent sensing film (Y-CDs@BCM) was fabricated by anchoring yellow-emitting carbon dots (Y-CDs) into bacterial cellulose films, which enables rapid and sensitive detection of Cu2+ in complex real-world samples. The yellow fluorescent carbon dots (Y-CDs) were synthesized with the aid of o-phenylenediamine and 1-octyl-3-methylimidazolium tetrafluoroborate as precursors, exhibiting excellent fluorescence stability. The fluorescence of Y-CDs was selectively quenched by Cu2+ via the inner filter effect (IFE), allowing quantitative analysis with superior sensitivity compared to existing methods. By adding bacterial cellulose (BC) as a solid support, aggregation-induced fluorescence quenching was effectively reduced, and sensor robustness and portability were improved. Through smartphone-based colorimetric analysis, the Y-CDs@BCM sensor enabled rapid, visual interpretation of Cu2+ detection (within 1 min). Furthermore, cell viability and in vivo assays confirmed the biocompatibility of Y-CDs, indicating their suitability for biological imaging. This work presents an environmentally friendly, reliable, and practical method for on-site Cu2+ monitoring, emphasizing its broad application potential in food safety control and environmental analysis.
Abstract licence: CC BY
Artem Ulihin, Dmitry Novozhilov, Nikolai Uvarov
Batteries, 2023
Solid electrolytes prepared by the addition of LiBF4 to the plastic phase of [N13pyr]BF4 were prepared, and their physical and electrical properties were investigated. The electrolytes [N13pyr]BF4-LiBF4 containing 8–20 wt% LiBF4 are solid at temperatures below 80 °C and have a high ionic conductivity ~10−3–10−2 S cm−1 at 60 °C. Based on the results of DSC and conductivity studies, the phase diagram of the [N13pyr]BF4-LiBF4 binary system was plotted, and the formation of a new compound, 3[N13pyr]BF4·2LiBF4 was proposed. The existence of the new phase was supported by X-ray diffraction data. Electrochemical measurements of cells with lithium electrodes were carried out to test the applicability of these materials in lithium batteries. The electrochemical window was determined to be more than 5 V. In contrast to earlier data obtained for similar systems, the preconditioning effect was not observed. Nevertheless, the solid electrolyte [N13pyr]BF4-LiBF4 system has high ionic conductivity and may be used in solid-state lithium-ion batteries.
Abstract licence: CC BY 4.0
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q2917126), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.